HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Proks, P. Articles by Ashcroft, F. Search for Related Content PubMed PubMed Citation Articles by Proks, P. Articles by Ashcroft, F. Social Bookmarking                What's this?

Sulfonylurea Stimulation of Insulin Secretion

¹ University Laboratory of Physiology, Oxford University, Oxford, U.K
² Department of Clinical Biochemistry, University of Cambridge, Addenbrooke’s Hospital, Cambridge, U.K

Sulfonylureas are widely used to treat type 2 diabetes because they stimulate insulin secretion from pancreatic ß-cells. They primarily act by binding to the SUR subunit of the ATP-sensitive potassium (K_ATP) channel and inducing channel closure. However, the channel is still able to open to a limited extent when the drug is bound, so that high-affinity sulfonylurea inhibition is not complete, even at saturating drug concentrations. K_ATP channels are also found in cardiac, skeletal, and smooth muscle, but in these tissues are composed of different SUR subunits that confer different drug sensitivities. Thus tolbutamide and gliclazide block channels containing SUR1 (ß-cell type), but not SUR2 (cardiac, smooth muscle types), whereas glibenclamide, glimepiride, repaglinide, and meglitinide block both types of channels. This difference has been exploited to determine residues contributing to the sulfonylurea-binding site. Sulfonylurea block is decreased by mutations or agents (e.g., phosphatidylinositol bisphosphate) that increase K_ATP channel open probability. We now propose a kinetic model that explains this effect in terms of changes in the channel open probability and in the transduction between the drug-binding site and the channel gate. We also clarify the mechanism by which MgADP produces an apparent increase of sulfonylurea efficacy on channels containing SUR1 (but not SUR2).

CiteULike

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				X. Fan, Y. Ding, H. Cheng, D. X. Gram, R. S. Sherwin, and R. J. McCrimmon Amplified Hormonal Counterregulatory Responses to Hypoglycemia in Rats After Systemic Delivery of a SUR-1-Selective K+ Channel Opener? Diabetes, December 1, 2008; 57(12): 3327 - 3334. [Abstract] [Full Text] [PDF]

				M. A. Burke, R. K. Mutharasan, and H. Ardehali The Sulfonylurea Receptor, an Atypical ATP-Binding Cassette Protein, and Its Regulation of the KATP Channel Circ. Res., February 1, 2008; 102(2): 164 - 176. [Abstract] [Full Text] [PDF]

				N. Bahi-Buisson, M. Eisermann, S. Nivot, C. Bellanne-Chantelot, O. Dulac, N. Bach, P. Plouin, C. Chiron, and P. de Lonlay Infantile Spasms as an Epileptic Feature of DEND Syndrome Associated With an Activating Mutation in the Potassium Adenosine Triphosphate (ATP) Channel, Kir6.2 J Child Neurol, September 1, 2007; 22(9): 1147 - 1150. [Abstract] [PDF]

				M. Winkler, D. Stephan, S. Bieger, P. Kuhner, F. Wolff, and U. Quast Testing the Bipartite Model of the Sulfonylurea Receptor Binding Site: Binding of A-, B-, and A + B-Site Ligands J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 701 - 708. [Abstract] [Full Text] [PDF]

				M. Shigeto, M. Katsura, M. Matsuda, S. Ohkuma, and K. Kaku Nateglinide and Mitiglinide, but Not Sulfonylureas, Induce Insulin Secretion through a Mechanism Mediated by Calcium Release from Endoplasmic Reticulum J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 1 - 7. [Abstract] [Full Text] [PDF]

				K. Katsuno, Y. Fujimori, Y. Takemura, M. Hiratochi, F. Itoh, Y. Komatsu, H. Fujikura, and M. Isaji Sergliflozin, a Novel Selective Inhibitor of Low-Affinity Sodium Glucose Cotransporter (SGLT2), Validates the Critical Role of SGLT2 in Renal Glucose Reabsorption and Modulates Plasma Glucose Level J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 323 - 330. [Abstract] [Full Text] [PDF]

				J. F. Klement, Y. Matsuzaki, Q.-J. Jiang, J. Terlizzi, H. Y. Choi, N. Fujimoto, K. Li, L. Pulkkinen, D. E. Birk, J. P. Sundberg, et al. Targeted Ablation of the Abcc6 Gene Results in Ectopic Mineralization of Connective Tissues Mol. Cell. Biol., September 15, 2005; 25(18): 8299 - 8310. [Abstract] [Full Text] [PDF]

				P. Proks, C. Girard, and F. M. Ashcroft Functional effects of KCNJ11 mutations causing neonatal diabetes: enhanced activation by MgATP Hum. Mol. Genet., September 15, 2005; 14(18): 2717 - 2726. [Abstract] [Full Text] [PDF]

				P. Arkhammar, P. Wahl, B. Gerlach, T. Fremming, and J. B. Hansen Establishment and Application of in Vitro Membrane Potential Assays in Cell Lines with Endogenous or Recombinant Expression of ATP-Sensitive Potassium Channels (Kir6.2/SUR1) Using a Fluorescent Probe Kit J Biomol Screen, August 1, 2004; 9(5): 382 - 390. [Abstract] [PDF]